Press coverage about The Medicines (NASDAQ:MDCO) has trended somewhat positive recently, according to Accern Sentiment. The research group ranks the sentiment of press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. The Medicines earned a media sentiment score of 0.12 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 46.6067033983367 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Here are some of the news headlines that may have effected Accern Sentiment’s analysis:
A number of equities research analysts have recently commented on the stock. BidaskClub upgraded shares of The Medicines from a “sell” rating to a “hold” rating in a report on Thursday, March 15th. Oppenheimer restated a “buy” rating on shares of The Medicines in a report on Thursday, March 22nd. ValuEngine upgraded shares of The Medicines from a “sell” rating to a “hold” rating in a research report on Thursday, March 1st. Zacks Investment Research downgraded shares of The Medicines from a “buy” rating to a “hold” rating in a research report on Friday, February 2nd. Finally, Jefferies Group restated a “buy” rating and set a $47.00 price objective on shares of The Medicines in a research report on Friday, February 23rd. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $50.00.
Shares of NASDAQ:MDCO traded down $1.26 on Friday, reaching $29.76. The company’s stock had a trading volume of 988,616 shares, compared to its average volume of 1,171,874. The Medicines has a 52-week low of $24.45 and a 52-week high of $55.95. The company has a quick ratio of 3.18, a current ratio of 3.21 and a debt-to-equity ratio of 26.06. The stock has a market capitalization of $2,273.25, a P/E ratio of -3.54 and a beta of 0.65.
The Medicines (NASDAQ:MDCO) last released its quarterly earnings results on Wednesday, February 21st. The company reported ($2.19) EPS for the quarter, missing analysts’ consensus estimates of ($1.48) by ($0.71). The Medicines had a negative return on equity of 316.40% and a negative net margin of 1,035.27%. The firm had revenue of $8.60 million for the quarter, compared to analysts’ expectations of $20.71 million. During the same period in the prior year, the firm posted ($1.19) earnings per share. The Medicines’s revenue for the quarter was down 50.6% on a year-over-year basis. analysts expect that The Medicines will post -2.71 earnings per share for the current year.
In related news, Director William Crouse sold 7,500 shares of The Medicines stock in a transaction dated Wednesday, March 21st. The shares were sold at an average price of $32.26, for a total transaction of $241,950.00. Following the completion of the sale, the director now owns 60,633 shares in the company, valued at approximately $1,956,020.58. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 8.22% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “The Medicines (MDCO) Receives Coverage Optimism Rating of 0.12” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another website, it was stolen and reposted in violation of US and international copyright & trademark laws. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2018/04/07/the-medicines-mdco-given-daily-media-sentiment-rating-of-0-12.html.
About The Medicines
The Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin).
Receive News & Ratings for The Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines and related companies with MarketBeat.com's FREE daily email newsletter.